Category - Markets

Markets

Zomedica Pharma listed on TSX Venture

The shares of Zomedica Pharmaceuticals (TSX-V:ZOM), a veterinary pharmaceutical company, have been listed on TSX Venture Exchange under the symbol, ZOM. “With our shares trading on TSX-V, Zomedica has a more-efficient...

May 2, 2016

Markets

Canaccord ups Spectranetics price target to $23.50

Canaccord Genuity has raised its price target on Spectranetics (NASDAQ:SPNC) to $23.50 from $20. The stock closed at $16.68 on Thursday. “Our bullish conviction heading into the Q1 print was validated by the strong...

April 29, 2016

Markets

HCW starts Strongbridge Biopharma at buy

H.C. Wainwright has initiated coverage of Strongbridge Biopharma (NASDAQ:SBBP) with a “buy” rating and $15 price target. The stock closed at $5.23 on Tuesday. “Within the span of two years, Strongbridge has made...

April 27, 2016

Markets

Leerink downgrades Trovagene to market perform

Leerink Partners has downgraded Trovagene (NASDAQ:TROV) to “market perform” from “outperform” and lowered its price target to $4.50 from $8, following the recent removal/departure of key senior management. The stock...

April 26, 2016

Markets

Stifel starts Celator Pharma at buy

Stifel has initiated coverage of Celator Pharmaceuticals (NASDAQ:CPXX) with a “buy” rating and a 12-month target price of $23. The stock closed at $15.52 on Thursday. Analyst Stephen Willey writes that recently...

April 22, 2016

Markets

HCW starts Windtree Therapeutics at buy

H.C. Wainwright has launched coverage of Windtree Therapeutics (NASDAQ:WINT) with a “buy” rating and $8 price target, ahead of study readouts on tap for the next 12 months. The stock closed at $3.03 on Thursday. “We...

April 22, 2016

Markets

BTIG ups Cerus price target to $10

BTIG Research has raised its price target for Cerus (NASDAQ:CERS) to $10 from $8, saying the progress made by the company has “exceeded even our bullish expectations.” The stock closed at $6.65 on Thursday. Cerus is a...

April 22, 2016

Markets

Roth starts Foundation Healthcare at buy

Roth Capital Partners has initiated coverage of Foundation Healthcare (OTC:FDNH) with a “buy” rating and $6 price target. The stock closed at $3.05 on Monday. “The impetus for our buy rating is the potential of the...

April 19, 2016

Markets

Rodman starts Bio-Path at buy

Rodman & Renshaw has launched coverage of Bio-Path Holdings (NASDAQ:BPTH) with a “buy” rating and a 12-month price target of $5. The stock closed at $2.76 on Monday. “In our view, Bio-Path’s unique liposomal...

April 19, 2016

Markets

Rodman assumes coverage of Semler Scientific at buy

Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of Semler Scientific (NASDAQ:SMLR) with a “buy” rating and $8 price target. The stock was quoted at $2.05 Friday afternoon. Semler’s 2015 revenue of...

April 16, 2016

Category - Markets

Subscribe